Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
CD19 Expressing Malignancies, Hematologic Malignancy
About this trial
This is an interventional treatment trial for CD19 Expressing Malignancies
Eligibility Criteria
Inclusion Criteria:
- Relapsed or refractory CD19+ expressing malignancies
- At least 2 prior regimens per Standard of Care
Exclusion Criteria:
- No history of active CNS involvement
Sites / Locations
- Banner MDARecruiting
- City of HopeRecruiting
- Moffitt Cancer CenterRecruiting
- Tufts Medical CenterRecruiting
- Columbia UniversityRecruiting
- Thomas Jefferson UniversityRecruiting
- Lifespan Cancer Institute at Rhode Island HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Dose Level 1
Dose Level 2
Dose Level 3
In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL). Route of Administration: Intravenous injection/infusion.
In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL). Route of Administration: Intravenous injection/infusion.
In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL). Route of Administration: Intravenous injection/infusion.